Skip to main content

Table 3 Impact of the home-based infusions on Treatment Satisfaction in Enrolled population

From: Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond

 

Cohort A

(N = 32)

n (%)

Cohort B

(N = 6)

n (%)

Total

(N = 38)

n (%)

Number of patients who completed the home infusion satisfaction questionnaire at screening

32 (100.00)

6 (100.00)

38 (100.00)

Where do you prefer to take your ERT infusions?

   

Hospital/clinic near your home

1 (3.13)

0

1 (2.63)

Home

31 (96.88)

6 (100.00)

37 (97.37)

Why do you prefer to take your ERT infusion in home setting? a

   

More convenient

26 (81.25)

5 (83.33)

31 (81.58)

Less stressful

20 (62.50)

3 (50.00)

23 (60.53)

Daily activities are less disrupted

14 (43.75)

2 (33.33)

16 (42.11)

Work/school are less disrupted

8 (25.00)

3 (50.00)

11 (28.95)

Family life is less disrupted

8 (25.00)

3 (50.00)

11 (28.95)

Less transportation needed (drive, take bus/taxi/train)

21 (65.63)

3 (50.00)

24 (63.16)

More clinical supervision

3 (9.38)

1 (16.67)

4 (10.53)

Feel less socially isolated

1 (3.13)

1 (16.67)

2 (5.26)

Other

2 (6.25)

0

2 (5.26)

In general, and despite your LSD, would you say your health is:

   

Excellent

2 (6.25)

0

2 (5.26)

Very good

5 (15.63)

1 (16.67)

6 (15.79)

Good

16 (50.00)

5 (83.33)

21 (55.26)

Fair

4 (12.50)

0

4 (10.53)

Poor

5 (15.63)

0

5 (13.16)

If you are receiving ERT at home, how would you rate health in general compared to the period you received ERT in the hospital?

   

Much better now

6 (18.75)

3 (50.00)

9 (23.68)

Somewhat better now

6 (18.75)

2 (33.33)

8 (21.05)

About the same

19 (59.38)

1 (16.67)

20 (52.63)

Missing

1 (3.13)

0

1 (2.63)

  1. ERT = Enzyme Replacement Therapy, LSD = Lysosomal Storage Disease.
  2. Percentages were computed on patients belonging to the enrolled population within each considered group.
  3. Cohort A is consisting of Pompe disease patients receiving Myozyme in a homecare setting, while cohort B is composed of MPS I patients receiving Aldurazyme in a homecare setting.
  4. a More answers were allowed.